Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-240380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Gihwan Byeon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Kangwon National University Hospital, Chuncheon, Korea. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Amyloid beta-Peptides, Cholinesterase Inhibitors, Neuropsychological Tests. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Background
Clinical trial findings on cholinesterase inhibitors (ChEIs) for mild cognitive impairment (MCI) are inconclusive, offering limited support for their MCI treatment. Given that nearly half of amnestic MCI cases lack cerebral amyloid-β (Aβ) deposition, a hallmark of Alzheimer’s disease; this Aβ heterogeneity may explain inconsistent results.
Objective
This study aimed to assess whether Aβ deposition moderates ChEI effects on amnestic MCI cognition.
Methods
We examined 118 individuals with amnestic MCI (ages 55–90) in a longitudinal cohort study. Baseline and 2-year follow-up assessments included clinical evaluations, neuropsychological testing, and multimodal neuroimaging. Generalized linear models were primarily analyzed to test amyloid positivity’s moderation of ChEI effects on cognitive change over 2 years. Cognitive outcomes included Mini-Mental Status Examination score, the total score of the Consortium to Establish a Registry for Alzheimer’s Disease neuropsychological battery, and Clinical Dementia Rating-sum of boxes.
Results
The analysis found no significant ChEI use x amyloid positivity interaction for all cognitive outcomes. ChEI use, irrespective of Aβ status, was associated with more cognitive decline over the 2-year period.
Conclusions
Aβ pathology does not appear to moderate ChEI effects on cognitive decline in MCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuropsychiatry, Kangwon National University Hospital, Chuncheon, Korea.
- Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea.
- Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea.
- Institute of Human Behavioral Medicine, Medical Research Center Seoul National University, Seoul, Korea.
- Interdisciplinary Program of Cognitive Science, Seoul National University College of Humanities, Seoul, Korea.
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea.
Förderung
- NIA NIH HHS
Zitieren
APA
Byeon, G., Byun, M. S., Yi, D., Ahn, H., Jung, G., Lee, Y. S., Kim, Y. K., Kang, K. M., Sohn, C. H., Lee, D. Y., & KBASE Research Group (2024). Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240380
Vancouver
Byeon G, Byun MS, Yi D, Ahn H, Jung G, Lee YS, et al. Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240380
BibTeX
@article{Byeon2024,
author = {Byeon, Gihwan and Byun, Min Soo and Yi, Dahyun and Ahn, Hyejin and Jung, Gijung and Lee, Yun-Sang and Kim, Yu Kyeong and Kang, Koung Mi and Sohn, Chul-Ho and Lee, Dong Young and KBASE Research Group, KBASE Research Group},
title = {Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-240380}
}
EUVIMED